je.st
news
Home
› Pfizer Announces FDA Approval Of XELJANZ XR (tofacitinib citrate) Extended-Release Tablets, The First And Only Once-Daily Oral JAK Inhibitor Treatment For Rheumatoid Arthritis
Pfizer Announces FDA Approval Of XELJANZ XR (tofacitinib citrate) Extended-Release Tablets, The First And Only Once-Daily Oral JAK Inhibitor Treatment For Rheumatoid Arthritis
2016-03-02 04:30:55| drugdiscoveryonline Home Page
Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved XELJANZ XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX)
Tags: treatment
approval
oral
announces
Category:Biotechnology and Pharmaceuticals